• First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment
  • DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation
  • Fetal Growth Restriction white paper authored by leading maternal-fetal medicine experts released